Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for SAB Biotherapeutics (SABS) over the last 3 years, with Dec 2024 value amounting to $9.3 million.

  • SAB Biotherapeutics' Shares Outstanding (Diluted Average) rose 740.93% to $77.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 740.93%. This contributed to the annual value of $9.3 million for FY2024, which is 67.74% up from last year.
  • As of FY2024, SAB Biotherapeutics' Shares Outstanding (Diluted Average) stood at $9.3 million, which was up 67.74% from $5.5 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) ranged from a high of $9.3 million in FY2024 and a low of $4.4 million during FY2022.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $5.5 million (2023), whereas its average is $6.4 million.
  • Data for SAB Biotherapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 67.74% (in 2024) over the last 5 years.
  • Over the past 3 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $4.4 million in 2022, then rose by 26.86% to $5.5 million in 2023, then soared by 67.74% to $9.3 million in 2024.